Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06179212
Other study ID # 20230327-01H
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 21, 2024
Est. completion date November 20, 2024

Study information

Verified date May 2024
Source Ottawa Heart Institute Research Corporation
Contact Jennifer Reed, PhD
Phone 613-696-7392
Email jreed@ottawaheart.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to determine if the test that allows males to achieve a higher VO2 (a measure of oxygen use during exercise) is different for females. The purpose of this study is to test 4 different exercise testing protocols to compare measured oxygen consumption in females and males with CAD (disease caused by the buildup of plaque in the artery walls which can lead to insufficient amounts of blood, nutrients and oxygen being supplied to the heart). The 4 exercise tests that will be completed on the treadmill are the modified Balke, modified Bruce, modified Naughton and University of Ottawa Heart Institute Slow Ramp protocols. Each test has a different stage duration (the amount of time that the test remains at a pre-determined speed and incline), and incremental increase in speed and incline. The main purpose of this study is to compare VO2 peak (the maximal amount of oxygen utilized during the exercise test) of females and males with CAD in 4 different exercise protocols. For example, the investigators will find out: 1. which exercise protocol is more likely to achieve a higher peak V̇O2 in females and which protocol is more likely to achieve a higher peak V̇O2 in males, 2. if enjoyment affects the duration of the test, and 3. how different exercise test protocols will provide different results of maximal oxygen used by the participant's body during the exercise test.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 54
Est. completion date November 20, 2024
Est. primary completion date November 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years and older; 2. previous CAD diagnosis by a physician; 3. can perform a CPET until volitional exhaustion; 4. are able to self-ambulate on a treadmill; 5. are at least 8 weeks post cardiovascular event or procedure (i.e., percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)); and, 6. are able to provide written informed consent. Exclusion Criteria: 1. cannot speak, read, write, or understand English or French; 2. currently not enrolled in a CR program; 3. have recently changed (or planning to change) PA levels within the previous 4 weeks (as this may impact the ability to compare outcomes between exercise testing protocols); 4. have heart failure with an ejection fraction <45% (indication of possible cardiomyopathy);6 5. have an arrythmia (relative contraindication for exercise testing),6 peripheral artery disease, valvular disease, severe aortic stenosis, cardiomyopathy, SCAD and/or COPD (contraindications for maximal exercise testing); 6. has an ICD; 7. is pregnant (sustained vigorous exercise in pregnant women may induce fetal bradycardia) 8. is unable to complete submaximal exercise testing (i.e., treadmill, due to musculoskeletal limitations).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Exercise Tests
Patients will complete 4 different cardiopulmonary exercise tests in random order.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Heart Institute Research Corporation

Outcome

Type Measure Description Time frame Safety issue
Primary Oxygen Consumption (VO2) V?O2 will be measured continuously throughout the treadmill CPET. Peak V?O2, defined as the highest V?O2 value that is achieved over a 20-s period during the last minute of the CPET. V?O2 will be measured throughout each test by a metabolic system (Parvo Medics TrueOne 2400). Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Blood pressure (BP) Resting BP (mmHg) will be measured from a seated position using an automated BP monitor. BP will be measured manually using a BP cuff every 2 stages throughout the CPET using an automated BP monitor. Recovery BP will be measured after the completion of the test from a seated position using the automated BP monitor. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Heart Rate (HR) Heart rate will be measured from a seated position using an automated BP monitor. HR will be measured continuously throughout the CPET using a 4-lead electrocardiogram connected to a metabolic system. Recovery HR will be measured after the completion of the test from a seated position using the automated BP monitor. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Body mass index Height (cm) and body mass (kg) will be measured to compute body mass index (kg/m2). Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Fat mass Fat mass (kg) and fat-free mass (kg) will be measured using bioelectrical impedance. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Waist circumference Waist circumference will be measured using standardized procedures (2 repeated measures using a tape; in centimeters). Week 1 to week 4 (measured weekly, at every appointment)
Secondary Cardiometabolic health indicators - Height Height will be measured using standardized procedures (2 repeated measures using a tape; in centimeters). Week 1 to week 4 (measured weekly, at every appointment)
Secondary Blood Lactate Blood lactate (mmol/L) will be measured in the last 30s of every test stage throughout the test using a blood lactate analyzer. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Rating of perceived exertion (RPE) Measured at the end of every stage using the validated Borg 6-20 rating of perceived exertion scale. This scale measures how physically exerted an individual feels. 6 is complete rest (i.e., no exertion, ex: sitting in a chair not moving and relaxed), 20 is perceived maximal exertion of effort. These values are perceived measures of effort and will increase as the exercise test progresses and gets harder for the patient. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Test duration Measured using portable metabolic system that is connected to a computer. The duration of the test will be recorded. Week 1 to week 4 (measured weekly, at every appointment)
Secondary Reason for test termination Reason for test termination will be collected subjectively by asking the patient (i.e., fatigue, muscular limitation, etc.) Week 1 to week 4 (collected weekly, at every appointment)
Secondary Physical activity enjoyment This is a subjective questionnaire that measures the extent to which the patient enjoyed participating in the test. Week 1 to week 4 (collected weekly, at every appointment)
Secondary Most enjoyed test Using a feedback questionnaire, the test that was most frequently ranked the most enjoyed by patients will be measured Week 4 - collected at the patient's last appointment
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A